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In recent years, mesenchymal stromal cells (MSCs) have been largely investigated and tested as a new therapeutic tool for
several clinical applications, including the treatment of different rheumatic diseases. MSCs are responsible for the normal
turnover and maintenance of adult mesenchymal tissues as the result of their multipotent differentiation abilities and their
secretion of a variety of cytokines and growth factors. Although initially derived from bone marrow, MSCs are present in
many different tissues such as many peri-articular tissues. MSCs may exert immune-modulatory properties, modulating
different immune cells in both in vitro and in vivomodels, and they are considered immune-privileged cells. At present, these
capacities are considered the most intriguing aspect of their biology, introducing the possibility that these cells may be used as
effective therapy in autoimmune diseases. Therefore, stem cell therapies may represent an innovative approach for the
treatment of rheumatic diseases, especially for the forms that are not responsive to standard treatments or alternatively still
lacking a deﬁnite therapy. At present, although the data from scientiﬁc literature appear to suggest that such treatments might
be more effective whether administered as soon as possible, the use of MSCs in clinical practice is likely to be restricted to
patients with a long history of a severe refractory disease. Further results from larger clinical trials are needed to corroborate
preclinical ﬁndings and human non-controlled studies, and advancement in the knowledge of MSCs might provide infor-
mation about the therapeutic role of these cells in the treatment of many rheumatic diseases.
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In recent years, mesenchymal stromal cells (MSCs)
have been largely investigated and tested as a new
therapeutic tool for several clinical applications,
including the treatment of different rheumatic dis-
eases. MSCs are responsible for the normal turnover
and maintenance of adult mesenchymal tissues as the
result of their multipotent differentiation abilities and
their secretion of a variety of cytokines and growth
factors. MSCs are deﬁned according to the criteria
proposed by the International Society for Cellular
Therapy: (i) MSCs must be plastic-adherent in stan-
dard culture conditions; (ii) They must express
CD105, CD73 and CD90 but lacking in the expres-
sion of CD45, CD34, CD14 or CD11b, CD79a,
CD19 and the major histocompatibility complex
(MHC) class II cell surface receptor, HLA-DR; (iii)
They must be able to differentiate toward osteoblasts,Correspondence: Paola Cipriani, MD, Rheumatology Unit, Clinical Science and
E-mail: paola.cipriani@cc.univaq.it
(Received 25 July 2014; accepted 1 December 2014)
ISSN 1465-3249 Copyright  2015, International Society for Cellular Therapy. P
http://dx.doi.org/10.1016/j.jcyt.2014.12.006adipocytes and chondroblasts in vitro [1]. Besides
these three lineages, according to environmental fac-
tors such as growth factors, hypoxia and the extracel-
lular three-dimensional environment, MSCs may
differentiate into other different cell types [2].
Although initially derived from bone marrow (BM),
where they reside in a perivascular location and ex-
press markers speciﬁc for pericytes [2], MSCs are
present in many different tissues. In fact, MSCs may
be isolated from many peri-articular tissues including
synovium, synovial ﬂuid, cartilage, intra-articular fat
and periosteum. Adipose tissue is a major source of
adipose derived stromal cells (ADSCs) [3]. ADSCs
aremainly located in the stroma, and only few of them
display a perivascular location. Their transcriptomic
and proteomic proﬁles show some speciﬁcities linked
to their tissue origin, reﬂecting the inﬂuence of the
microenvironment. Of note, ADSCs show angiogenicBiotechnology Department, University of L’Aquila, 67100 L’Aquila, Italy.
ublished by Elsevier Inc. All rights reserved.
2 P. Cipriani et al.potential through trans-differentiation toward the
endothelial phenotype; they control the evolution of
scars through their antiﬁbrotic effects and protect
against apoptosis [4,5].
MSCsmay exert immune-modulatory properties,
modulating different immune cells in both in vitro
and in vivo models [3e5], through both cell con-
tactedependent mechanisms and soluble factors
[6,7], mainly resulting in the generation of cells with
regulatory activity [8e10]. MSCs are considered
immune-privileged cells: they express low levels of
cell-surface HLA class I molecules, whereas HLA
class II, CD40, CD80 and CD86 are not detectable
on the cell surface, and this phenotype might allow
escape to the immune surveillance [11]. Although
many rheumatic diseases, and mainly the autoim-
mune diseases, reﬂect a pathological activation of the
immune system and activation of the inﬂammatory
cascade, the potential role of an altered microenvi-
ronment may be considered, including a disturbance
of resident MSCs. Several results, available in liter-
ature, suggest that despite some functional defects of
resident MSCs, they may continue to exert immune
modulatory effects and many functional defects may
be reverted in vitro, suggesting a potential role of
autologous MSC transplantation in autoimmune
diseases. On the other hand, their immune privilege
offers the possibility of easier allogeneic trans-
plantation, overcoming the self-recognition barrier.
Thus, at present, both the possibilities—autologous
and allogeneic transplantation—may be considered,
and the results of future clinical trials will suggest the
best choice for any different rheumatic disease.
However, it must be pointed out that both their
immunologically privileged phenotype and immu-
nosuppressive skills may be considered the most
intriguing aspects of their biology, which suggests
that these cells may be used as effective therapy in
autoimmune diseases [3,6,10,12e14].
In this review, we report the results available in
the literature concerning the therapeutic role of
MSCs in rheumatic diseases.Osteoarthritis
Chronic disability in people over 50 years of age is
strongly associated with disorders of the musculo-
skeletal system, and osteoarthritis (OA) involving the
spine and diarthrodial joints is the most common
condition. All joints can be affected by OA, but the
hand, knee and hip represent the main targets of the
disease [15]. OA has an enormous social and eco-
nomic burden, increasing in parallel with population
age [16]. Moreover, OA is associated not only with
disability but also with other conditions, such as
obesity, neuropathic pain, trauma, depression andsleep disorders, and may be an important cause of
premature death [17,18].Pathogenesis
OA is a complex condition characterized by degener-
ation of the articular cartilage, which is accompanied
by damage of the underlying bone, sub-chondral bone
sclerosis, development of cysts and osteophytes and
synovial inﬂammation. Destruction of articular carti-
lage stimulates synovial lining cells and articular
chondrocytes to synthesize and secrete proteolytic
enzymes: matrix metalloproteinase, aggrecanase, pro-
inﬂammatory cytokines and solublemediators such as
nitric oxide and prostaglandins, which degrade the
cartilaginous matrix and accelerate articular cartilage
degradation [19e21]. OA has been considered a non-
inﬂammatory condition for some time; however,
increasing evidence supports that inﬂammation is
present in the synovial tissue of OA, raising the hy-
pothesis that synovitis and the immune system could
be active players in OA development and progression
[22]. Synovial inﬂammation occurs in the majority of
OA patients and is a predictive factor for disease pro-
gression [23e25].
Current treatments produce symptomatic rather
than regenerative results and include pain control
(steroidal and non-steroidal anti-inﬂammatory
drugs), viscosupplementation (injections of sodium
hyaluronate) and a variety of nutraceuticals (chon-
droitin sulphate, glucosamine, omega-3 fatty acids).
None of these compounds has a useful impact on the
progressive loss of joint tissues [26]. Joint-resident
MSCs in humans were ﬁrst described in synovial
membrane [27], but it is well known that MSCs, or
cells with properties very similar to MSCs, can be
detected in different tissues of diarthrodial joints, such
as the synovialﬂuid compartment, the synovial fat pad,
the articular cartilage surface zone, ligaments and the
meniscus [28e31]. These cells share the same surface
markers and functions of BM-derived MSCs. How-
ever, minor phenotypic differences between different
populations of joint-resident MSCs may reﬂect their
speciﬁc tissue of origin or, alternatively, the inﬂuence
of culture conditions used for their isolation [32].
The widespread distribution of MSCs in dia-
rthrodial joints is associated with key functional
characteristics that contribute to the maintenance of
healthy tissues and/or their ability to respond to
injury. These cells provide a reservoir of repairing
cells that are activated in response to growth,
remodeling or repair. Furthermore, they might act as
immune system sentinels to reduce inﬂammation or
modulating T-cell activation [25,27].
Several reports suggest that MSCs are depleted
in the marrow of patients with advanced OA and that
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higher concentrations of growth factors are required
to support their proliferation and differentiation.
Murphy et al. [33] demonstrated that MSCs ob-
tained from BM during joint replacement surgery in
patients with end-stage OA were functionally deﬁ-
cient in terms of in vitro proliferation and differen-
tiation. These functional deﬁciencies can be reversed
by supplementation of the culture medium enriched
by epidermal growth factor or ﬁbroblast growth
factor 2 [34,35]. Indeed, inclusion of ﬁbroblast
growth factor 2 in the culture medium promoted
proliferation and inhibited senescence through the
phosphatidylinositol 3-kinase-AKT and E3
ubiquitin-protein ligase Mdm2 pathways, respec-
tively [36].
Other studies have suggested that the role of
aging inﬂuences MSC phenotype. In particular,
human periosteal MSCs from younger donors
exhibit spontaneous chondrogenic activity in cul-
ture, whereas such activity is absent in cells from
older donors [37]. Moreover, MSCs isolated from
trabecular bone samples from OA patients showed
an in vitro aging-related loss of proliferation when
compared with that in healthy donors [38].
As far as the pathogenetic role of MSCs or MSC-
like progenitor cells in OA is concerned, it must be
pointed out that a large number of Notch-1epositive
cells are found in articular cartilage from patients
with OA when compared with normal control sub-
jects, mainly located in clusters of proliferating cells
[39]. The presence of Notch-1 expression has been
associated with MSC-like cells and progenitor pop-
ulations in normal cartilage [30]. On this basis,
chondrocyte clusters, a hallmark feature of OA
articular cartilage, might be considered the result not
only of the de-differentiation and subsequent prolif-
eration of resident chondrocytes but also related to
the migration of progenitor cells [40].
The interplay between transforming growth factor
(TGF)-b, A-disintegrin and metalloproteinase with
thrombospondinmotifs 5 (ADAMTS5) and cartilage-
resident and/or bone-resident MSCs in OA may be
involved in the inappropriate cartilage repair response.
ADAMTS5 is the main aggrecanase involved in
degradation of mouse cartilage [41], and studies
concerning Adamts5e/e mice with experimental OA
showed that the lack of this metalloproteinase activity
resulted in a decrease of joint ﬁbrosis and evidence of
cartilage erosions [42,43]. Furthermore, in the pres-
ence of ADAMTS5, TGF-b is a ﬁbrosis inducer,
through TGF-b receptor type 1 (also known as Alk5)
and subsequent phosphorylation of Smad2 and
Smad3. On the contrary, lacking ADAMTS5, TGF-b
is an inducer of chondrogenesis through serine/
threonine-protein kinase receptor R3 (also known asAlk1) and subsequent phosphorylation of Smad1,
Smad5 and Smad9 [44].Preclinical results
Because of the ability of MSCs to synthesize cartilage
and bone, thus enhancing joint repair and reducing
the degenerative changes, it is appealing to suggest
that the replacement of defective populations by
MSC transplant may represent an attractive thera-
peutic option (Figure 1).
The effectiveness of intra-articular delivery of
autologous MSCs has been tested in a variety of
preclinical animal models of surgically induced OA,
post-traumatic OA, collagenase-induced OA and
spontaneous OA [45]. MSCs were seeded into three-
dimensional biodegradable scaffolds before implan-
tation into cartilage. Direct intra-articular injection
might be possible in early stages of the disease when
the defect is restricted to the cartilage layer, whereas
a scaffold would be required to support the MSCs in
the case of sub-chondral bone defect exposed over
large areas [46]. Treatment of post-traumatic OA in
goats through direct intra-articular delivery of a
suspension of goat MSCs elicited a meniscal repair
response, resulting in a signiﬁcant improvement in
cell-treated joints when compared with controls, with
evidence of cartilage protection. Of note, newly re-
generated meniscal tissue consisted of host cells
associated with small numbers of transplanted cells,
which suggests that transplanted MSCs act as
building blocks for the formation of repair tissue and
inﬂuence the behavior of resident cells [47].
MSCs have been previously embedded into
different scaffolds for attachment and growth and
then implanted into cartilage defect by means
of open arthrotomy. These scaffolds include a
synthetic or natural extracellular matrix consisting
of hyaluronic acid and gelatin, bioceramic
scaffoldeb-tricalcium phosphate, ﬁbrin glue, poly-
lactic acid, hyaluronic gel sponge and collagen gel
[48]. In this setting, a bio-scaffold coated with TGF-
b3 for surgical replacement of the synovial joint in
rabbits led to the formation of a useful and struc-
turally similar articular cartilage layer, with restora-
tion of function through the recruitment of
endogenous MSCs [49].
To avoid the risks of arthrotomy, the possibility of
the use of direct intra-articular injection of MSCs
suspended in hyaluronic acid for cartilage repair has
also been explored in different animal models of OA.
In these studies, autologous BM-derived MSCs com-
bined with a hyaluronan solution were injected into the
injured joints intra-articularly. Marked improvement in
cartilage healing and regeneration, reduced osteophyte
formation and sub-chondral sclerosis were observed in
Figure 1. The replacement of defective populations by MSCs transplant may represent an attractive therapeutic option for bone and
cartilage diseases. MSCs are able to induce cartilage synthesis during OA. When transplanted, the same cells, proliferate and differentiate to
osteoblasts in the bone, thus ameliorating OI, ONFH and OP.
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saline-treated controls [48].
In collagenase-induced and surgery-induced
models of OA mice treated with kartogenin, which
improves matrix structure and weight-bearing ability,
chondrogenic activation of resident progenitor cells
in the cartilage increased [50]. Kartogenin binds the
FC-1 fragment of ﬁlamin-A, disrupting its associa-
tion with core-binding factor b-subunit (CBFb), part
of a heterodimeric transcription factor complex.
Increased nuclear availability of CBFb leads to
activation of runt-related transcription factor
1 (RUNX1) and its associated network of genes,
which are important in chondrogenesis and tissue
repair [51,52].
At present, MSCs have been mainly obtained
from BM through the use of a highly invasive pro-
cedure; however, ADSCs show similar characteris-
tics when compared with BM-derived MSCs and
provide an abundant and easily accessible cell source
for cartilage repair. In fact, in dogs with chronic
osteoarthritis of the coxofemoral and humeroradial
joints, a clinically signiﬁcant improvement wasobserved in ADSC-treated joints when compared
with controls [53,54].
Human umbilical cordederived MSCs (UC-
MSCs), isolated from extra-embryonic tissue
(Wharton’s jelly) after birth, are a promising candidate
source of MSCs with several advantages: abundant
supply, painless collection, no donor site morbidity
and faster and longer self-renewal ability in vitro [55].
When compared with BM-derived MSCs and under
speciﬁc conditions, UC-MSCs are able to produce
more glycosaminoglycans, aggregans and type I
collagen and show enhanced cell attachment, cell
proliferation and chondrogenesis [56,57].Clinical therapy
Preclinical observations provided the rationale to
pursue MSC therapeutic application in vivo in OA.
Wakitani et al. [58] performed the ﬁrst clinical study
on 24 patients with OA who underwent a tibial
osteotomy. Autologus BM-derived MSCs,
embedded in collagen gel, were transplanted into the
articular cartilage defect and covered with
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transplantation, the defects were covered with white
soft tissue, and hyaline cartilageelike tissue was
partially observed. The arthroscopic and histological
grading score signiﬁcantly improved in the cell-
transplanted group when compared with the cell-
free control group [58]. To avoid invasive surgery,
percutaneous injection of MSCs was used in a small
cohort of patients with knee osteoarthritis. The
autologous MSCs derived from adipose tissue of
abdominal origin, combined with hyaluronic acid,
platelet-rich plasma, calcium chloride and a nano-
gram dose of dexamethasone, were injected. At week
12, patient pain improved more than 90%; the range
of motion also improved, and magnetic resonance
imaging showed a signiﬁcant increase in the thick-
ness of meniscus cartilage on the knees [59].
Presently, several clinical trials are currently
ongoing, and the majority of these studies use
autologous, culture-expanded MSCs from BM or
adipose tissue, and, in a few cases, allogeneic MSCs,
derived from BM or cord blood. In the majority of
cases, intra-articular administration of MSCs is car-
ried out directly to the synovial ﬂuid compartment,
and the scaffold is replaced with a vehicle, mostly
hyaluronic acid, which represents a normal compo-
nent of extracellular matrix and is currently used for
therapeutic purposes in OA. Although the majority of
ongoing trials tested a cell injection dose of 1e4 
107 cells in a single injection, dose-ﬁnding studies are
required to identify the optimal cell dose leading to
the best outcome [25].Rheumatoid arthritis
Rheumatoid arthritis (RA) is a common autoim-
mune disease that is associated with progressive
disability, systemic complications, early death and
socioeconomic costs. The cause of RA is unknown.
However, advances in understanding the pathogen-
esis of the disease have fostered the development of
new therapeutics, with improved outcomes. The
current treatment strategy is to initiate aggressive
therapy soon after diagnosis and to escalate the
therapy, guided by an assessment of disease activity,
in pursuit of clinical remission [60].Pathogenesis
Recently, published data reported that BM-derived
MSCs from RA patients showed chondrogenic po-
tential that was similar to that observed in MSCs
isolated from healthy control subjects [61]. In this
study, marrow samples were collected during bone
surgery and adherent cell cultures were established
from patients with RA, patients with osteoarthritisand healthy control subjects. The authors docu-
mented that culture-expanded MSCs from RA and
OA patients did not differ signiﬁcantly from the
normal population with respect to their chondro-
genic potential in vitro. The ability of total protein
and proteoglycan synthesis and collagen II
messenger RNA expression by cell aggregates was
similar for all cell preparations in the presence of the
appropriate growth and differentiation factors.
However, synovial membraneederived MSCs from
patients with active RA were spontaneously defec-
tive, in terms of their clonogenicity and chondro-
genic differentiation potential, in the absence of
appropriate stimuli. In fact, a negative relationship
among synovial MSCs and chondrogenic and clo-
nogenic capacities, on the one hand, and the
magnitude of inﬂammatory synovitis in RA patients,
on the other hand, was reported in RA patients [62].
The possible role of MSCs in the immunopa-
thology of RA has been suggested by Marinova-
Mutafchieva et al. [63]. The authors aimed to
determine the involvement of MSCs in the induction
of collagen-induced arthritis (CIA). An analysis of the
joints at day 10 after immunization with type II
collagen in adjuvant versus adjuvant alone revealed
synovial hyperplasia without leukocytic inﬁltration.
Large, round cells expressing bone morphogenetic
protein receptors (BMPRs), which serve as markers for
primitive MSCs, were present in increased numbers in
the BM adjacent to the joint, in the synovium, and
within the enlarged bone canals connecting BM to the
synovium. Similar changes were observed in mice
receiving adjuvant without collagen. Adjuvant-induced
inﬁltration of BMPRþ cells and enlargement of bone
canals were abrogated by antietumor necrosis factor-a
(antieTNF-a) treatment and were absent in TNFR
p55/p75(/) mice. Increased numbers of BM cells
and enlarged bone canals were observed in non-
immunized TNF-a transgenic mice (which sponta-
neously develop arthritis). Therefore, it has been
postulated that BM-derived stromal cells might
migrate to the joint space before the onset of acute
inﬂammation in the TNF-a transgenic mouse model.
In these animals, antieTNF-a therapy inhibits local
migration of BM stromal cells and prevents the clin-
ical signs of arthritis [63].
It has been further hypothesized that RA syno-
viocytes might be transformed into BM-derived
MSCs stuck at early stages of differentiation by
pro-inﬂammatory factors. This evidence suggested
that the abnormal phenotype of RA ﬁbroblast-like
synoviocytes might derive from an aberrant activa-
tion of mechanisms that normally serve to provide
physiological repair of joint tissues. Arthritogenic
stimuli provide aberrant production of damage sig-
nals that cause sustained inﬂux of BM-derived MSCs
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appear as a heterogeneous population of under-
differentiated MSCs, arrested at intermediate stages
of differentiation by the inﬂammatory milieu [64].Preclinical results
Studies of MSCs as cellular therapy for CIA reported
conﬂicting results. The ﬁrst study that used MSCs,
administered intravenously in mice, showed that
there was no beneﬁt of cellular therapy for the
reduction of CIA [65]. On the contrary, another
study showed that a single intraperitoneal (IP) in-
jection of allogeneic MSCs in mice prevented the
development of severe arthritis. MSCs did not
localize to the joints, which suggests that the clinical
improvement was not due to their ability to repair the
joints but probably by reducing the levels of pro-
inﬂammatory cytokines, such as IL-10, and de novo
generation of T-regulatory (Treg) cells [66].
Further positive results from MSC therapy were
reported after daily IP injection of human or murine
allogeneic and syngeneic adipose ADSCs. After the
onset of the disease, 5 days of treatment signiﬁcantly
reduced the incidence and severity of arthritis in the
CIA model. Conversely, intra-articular injection of
ADSCs was less effective than was the IP route. In
this context, after collecting cells from lymph nodes
of MSC-treated mice, a signiﬁcant decrease of Th1
cytokines and Th17 cytokine was observed, whereas
the levels of the regulatory cytokines such as IL-10
were increased [67,68].
Other studies, however, failed to demonstrate any
improvement in experimental CIA with MSC treat-
ment. One study showed that MSCs exacerbated the
arthritis in mice by promoting the secretion of IL-6
and IL-17 [69]. Schurgers et al. [70] were unable
to demonstrate any beneﬁt from MSC therapy in
CIA [70]. In contrast, injection of Treg cells before
or after disease onset led to a dramatic improvement
in arthritis. One study examined the effect of human
allogeneic ADSCs on collagen-reactive T cells iso-
lated from patients with RA in vitro [71]. These cells
inhibited both the proliferation and the expression of
pro-inﬂammatory cytokines by collagen-activated T
cells, whereas an increased number of IL-
10eproducing T cells was reported. Furthermore,
these cells impaired the production of the matrix-
degrading enzymes collagenase and gelatinase,
which are involved in the inﬂammatory response. In
addition, results from recent studies further support
the potential of MSCs in the treatment of autoim-
mune inﬂammatory arthritis; in fact, immune mod-
ulation and reduction of articular damage after
treatment with MSCs were observed [71]. These
ﬁndings suggest that MSC therapy may be able toreset the immune system by reducing the deleterious
Th1/Th17 response and enhancing the protective
Treg cell response.
Clinical therapy
These above-mentioned experiences suggest that
MSCs might exert a profound inhibitory effect on the
proliferation, invasive behavior and inﬂammatory re-
sponses of synoviocytes, suppress T-cell activation
and induce the generation of Tregs. Furthermore,
cell-based therapy with the use of human MSCs
signiﬁcantly ameliorated CIA in mice. These data
suggest that MSCs might open new therapeutic per-
spectives in RA as observed in other rheumatic dis-
eases (Table I). Future studies must clarify whether
the in vitro ability of MSCs to generate de novo Treg
cells might be considered a safer and helpful thera-
peutic option when compared with neutralizing anti-
bodies against single-cytokine signaling [72e74]. At
present, many clinical trials are ongoing (http://www.
clinicaltrials.gov/), aiming to evaluate safety and efﬁ-
cacy of MSC treatment in RA patients.
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic
autoimmune disease that involves multiple organs
including renal, cardiovascular, neural, musculoskel-
etal and cutaneous systems with a remarkable vari-
ability in clinical presentation. The pathogenesis of
SLE is a complex interplay of genetic, endogenous and
environmental stimuli, resulting in a breakdown of self-
tolerance and development of autoimmunity with or-
gan damage. Major organ manifestations, particularly
central nervous system and renal disease, have long
been identiﬁed as markers of poor prognosis [75,76].
Although the most widely and classically used
immunosuppressive therapies led to a signiﬁcant
improvement in survival over recent years, these
treatments often result in serious side effects such as
infection, ovarian failure and secondary malignancy,
and the disease often relapses after drug withdrawal
[77,78].
Pathogenesis
In recent years, impaired capacities of proliferation,
differentiation, secretion of cytokines and immune
modulation of BM-derived MSCs from patients with
SLE were reported [79]. BM-derived MSCs from
SLE patients may be successfully culture-expanded,
but these cells grew more slowly than did those of
normal control subjects. Several abnormalities of
cytoskeleton were found that might explain the
decreased cell expansion in vitro, which are probably
related to different gene expressions of cytoskeleton
Table I. Main results of available literature concerning the therapeutic role of MSCs in rheumatic diseases.
Disease
[Reference] MSCs type Route of administration Patients Outcome
OA [41] Autologous BM-derived MSCs Injected in to involved joint 24 Improvement of clinical,
arthroscopic and histological
grading scores
OA [42] Autologous adipose tissue–derived
MSCs
Injected into involved joint 4 Improvement of clinical and
magnetic resonance data
SLE [77] Allogeneic BM- or UC-derived
MSCs
Systemic administration 87 Improvement of disease activity
and serologic feature
SLE [78] Autologous BM-derived MSCs Systemic administration 2 No change in disease activity
indexes
SSc [88] Allogeneic haploidentical-related
donor MSCs
Systemic administration 5 Improvement of skin score and
acral necrosis
SSc [89] Autologous adipose tissue–derived
MSCs
Systemic administration 6 Improvement of skin score
OI [96] Allogeneic haploidentical-related
donor MSCs
Systemic administration 3 Increase of dense bone formation
and body mineral content
OI [98] Allogeneic HLA-mismatched male
fetal MSCs
In utero at 32nd week of
gestation
1 During the ﬁrst 2 years of life, 3
fractures were noted
ONFH [113] Autologous BM-derived MSCs Implantation in femoral head 19 Reduction of pain and joint
symptoms
ONFH [114] Autologous BM-derived MSCs Implantation in femoral head 100 Improvement of clinical conditions
and decrease of necrotic area
Mesenchymal stromal cells and rheumatic diseases 7components of BM-derived MSCs in these patients
[80,81]. Despite this ﬁnding, MSCs from SLE have a
normal karyotype: these cells express CD29, CD44
and CD105 and lack CD14, CD34, CD45 and
HLA-DR. Furthermore, these MSCs were defective
in secreting cytokines such as TGF-b, and a down-
regulation of IL-6 and IL-7 messenger RNA
expression was reported [80].
Some authors recently showed that expression of
the p16 cyclin-dependent kinase inhibitor 4A (p16-
INK4A) gene was signiﬁcantly increased, whereas
the levels of CDK4, CDK6 and p-Rb expression
were decreased in the MSCs from SLE patients.
Furthermore, they showed that p16INK4A might be
the major factor involved in the cellular senescence
process of MSCs from SLE patients by regulating
cytokine secretion and the ERK1/2 signaling
pathway. This evidence might explain why MSCs
from SLE patients displayed prominent senescent
characteristics [82]. In fact, these cells were found to
be larger and ﬂattened in appearance, with a slower
growth rate, compared with ﬁbroblast-like MSCs
from normal control subjects. Telomerase activity
was upregulated in the MSCs of SLE patients, par-
alleling the disease activity, and these cells showed
early signs of senescence, which might be a contrib-
utory factor to disease pathogenesis [83].
Of note, in bone marrow aspirates from SLE pa-
tients, an increased apoptosis of MSCs, a down-
regulation of Bcl-2 and an upregulation of cytochrome
Cwereobserved [84]. In addition, intracellular reactive
oxygen species (ROS), which appears to be the maincause of the senescence of humanMSCs [85,86], were
higher inSLEBM-derivedMSCs comparedwith those
of normal control subjects. It has been suggested that
the increased phosphorylation of Fox3, observed
in SLE MSCs, impairing the activation of FoxO3, re-
sults in the cytoplasmic sequestration and inhibition of
its downstream transcriptional activity, with produc-
tion of high levels of ROS, thus favoring senescence.
However, it is still unknownwhether this defect of BM-
derivedMSCs is primary or secondary. It is well known
that an increase in serum levels of IL-6, IL-10 and
TNFa is present during the disease and closely corre-
lates with SLE disease activity; speciﬁc receptors for
these cytokines are expressed by stem cells, and the
signaling mediated by these receptors may lead to an
alteration of MSC proliferation [87e90]. Therefore,
during SLE, some biological condition might impair
the functional integrity of stemcells, and further studies
must completely elucidate the role of these cells in the
complex pathogenetic scenario of the disease.Preclinical results
Therapies with autologous or allogeneic MSCs have
been tested in several SLE murine models
(Figure 2). Recently, in MRL/lpr mice, a disease
improvement was shown, in a dose-dependent
manner, after the injection of human MSCs from
healthy donors [91]. After transplantation with allo-
geneic MSCs, a reduction of serum levels of anti-
edouble-stranded DNA (anti-dsDNA) antibodies
and 24 hours of proteinuria in the same mice strain
Figure 2. MSCs might exert a profound inhibitory effect on the inﬂammatory responses, signiﬁcantly ameliorating CIA in mice. In addition,
MSCs therapy showed an improvement of nephritis during SLE, reduction of skin ﬁbrosis during SSc and reduction of inﬂamed mucosa
during inﬂammatory bowel diseases (IBD).
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subset and a decrease of the Th2 cell subset were
found. Histopathological examination pointed out a
signiﬁcant decrease of the renal injury in MSC-
treated mice with a signiﬁcant reduction of C3
deposition in renal tissue and improvement of glo-
merulosclerosis [91].
More recently, it has been shown that MSC
transplantation resulted in a signiﬁcant reduction in
serum levels of anti-dsDNA, reduction of glomerular
immunoglobulin G deposition and restoration of
glomerular structure, which suggests that MSCs
might be an effective therapeutic option for an
MRL/lpr lupus murine model [92].
Choi et al. [93] investigated the effects of long-
term serial human ADSC transplantation on SLE
in NZB/WF1 mice. A higher survival rate, with
improvement of histological and serological abnor-
malities associated with a decreased incidence of
proteinuria, was observed. In addition, a restoration
of CD4þ/FoxP3þ cells and cytokine production
were reported in transplanted NZB/WF1 mice [93].Despite these recent basic studies that have
clearly pointed out the potential of the use of MSCs
to treat SLE, the mechanisms by which MSCs exert
their immunomodulatory and reparative effects are
still largely unknown. It might be linked to multiple
mechanisms mediated by both soluble factors and
cell contact. In addition, it is possible that in-
teractions between immune cells and MSCs in the
tissue microenvironment might modulate MSC
function and contribute to the outcome of MSC-
based therapy [79].Clinical therapy
Supported by the clinical beneﬁts of MSCs therapy in
SLEmice,Wang et al. [94] carried out a study to assess
the safety and efﬁcacy of allogeneicMSC transplant in
patients with refractory SLE. Eighty-seven patients
with persistently active SLE, refractory to stan-
dard treatments or affected by a life-threatening
visceral involvement, were enrolled and successfully
transplanted with allogeneic BM-derived or umbilical
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ﬁndings of Carrion et al. [96], disease activity
decreased, as revealed by signiﬁcant changes in SLE
disease activity score and levels of serum autoanti-
bodies, albumin and complement factors. Of note,
in this context, no difference in disease remission
was observed between patients with or without
cyclophosphamide therapy pretreatment after 4 years
of follow-up, which strongly suggests that the repor-
ted clinical beneﬁts were not related to cytotoxic
therapy [95].
Although controlled, randomized studies must
understand the real place of this treatment in the
therapy of human SLE, these results suggest that
allogeneic MSC therapies are a safe procedure that
shows the ability to induce a good clinical response in
refractory SLE.Systemic sclerosis
Systemic sclerosis (SSc) is an autoimmune disease in
which vascular alterations, extensive ﬁbrosis and
autoantibodies against various cellular antigens are
the main clinical and pathogenetic features. SSc can
lead to severe dysfunction and failure of almost any
internal organ. The involvement of visceral organs is
a major factor in determining the prognosis [97].Pathogenesis
BM-derived MSCs from patients with SSc appeared
to be similar to those from healthy donors in their
phenotype and capacity to differentiate into adipo-
genic and osteogenic lineages. Larghero et al. [98]
assessed BM-derived MSC function and phenotype
in 12 patients with SSc and compared them with 13
healthy normal control subjects. The parameters
included (i) the number of colony-forming unit
ﬁbroblasts; (ii) the ability to differentiate along the
adipogenic and osteogenic lineages; (iii) the expres-
sion of speciﬁc cell surface antigens, which can
deﬁne the MSCs population; (iv) the ability to sup-
port normal hematopoiesis associated with the sup-
pression of in vitro lymphocyte proliferation. The
results showed that SSc MSCs displayed the same
phenotype and functional activities of healthy donor
MSCs [98].
However, our previous work provided evidence
that these cells showed both an impairment to ac-
quire the functions of mature endothelium when
induced to differentiate toward endothelial cells [99]
and an early senescence, as demonstrated by a
reduced telomerase activity [99,100].
Recent ﬁndings showed similarities between
pericytes and BM-derived MSCs. Because of difﬁ-
culties in pericyte isolation, in a previous work, weexplored the possibility of the use of BM-derived
MSCs as a pericyte surrogate, trying to clarify their
role in supporting neo-angiogenesis during SSc.
Both SSc and healthy control BM-derived MSCs
were treated with TGF-b and prostaglandin-derived
growth factoreBB to normally differentiate toward
pericytes. We showed that BM-derived MSCs iso-
lated from SSc patients displayed an upregulation of
pericyte-speciﬁc markers and a reduced proliferative
activity. With the use of a co-culture assay, in a
tridimensional scaffold of both BM-derived MSCs
and microvascular endothelial cells (MVECs), we
observed that SSc BM-derived MSCs improve
endothelial cell tube formation in speciﬁc stressed
conditions, such as a sub-optimal number of
cultured endothelial cells, thus behaving as pericytes.
They display a more mature and myoﬁbroblast-like
phenotype, probably related to microenvironmental
cues operating during the disease. After their co-
culture with healthy control MVECs, SSc BM-
derived MSCs underwent a phenotypic modulation
that re-programs these cells toward pro-angiogenic
behavior [101].
Recently, Guiducci et al. [102] tried to charac-
terize BM-derived MSCs from SSc patients for the
expression of factors implicated in three different
functions: MSC recruitment at sites of injury,
angiogenesis and ﬁbrosis. The study also analyzed
whether the production/release of bioactive media-
tors by MSCs were affected by cytokines that are
generally found upregulated in SSc serum and tis-
sues and whether these MSCs may modulate dermal
MVECs. In SSc MSCs, the basal expression of pro-
angiogenic factors was signiﬁcantly increased
compared with that in healthy control MSCs. SSc
MSC-conditioned medium showed a greater pro-
angiogenic effect on MVEC than did healthy con-
trol MSCs. According to the authors, SSc MSCs
appear to constitutively over-express and release
bioactive mediators/pro-angiogenic factors, possibly
supporting dermal MVEC angiogenesis [102].
Although several lines of evidence are present in
published literature on the role of MSCs in the
pathogenesis of SSc, conﬂicting and not fully eluci-
dated data are still available.Clinical therapy
Although senescent, SSc MSCs maintain consider-
able immunosuppressive properties and a normal
ability to generate functional Tregs. Therefore,
senescence does not represent a limitation for their
potential use, both in cellular and regenerative
medicine, to target SSc. In fact, BM-derived MSCs
might therefore be considered in an autologous
setting for therapeutic use in SSc [103].
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series available in literature about the use of MSCs to
treat SSc patients. The ﬁrst case report published in
literature showed that the infusion of MSCs from a
haploidentical allogeneic cell donor induced a
marked improvement in the modiﬁed Rodnan skin
thickness score in a patient with diffuse SSc, without
internal organ involvement [104]. Subsequently, a
34-year-old woman with SSc who had acute
gangrene of the upper and lower limbs was treated
with intravenous expanded autologous MSCs. Areas
of necrotic skin were reduced after the ﬁrst MSCs,
and, after the third infusion, angiography showed
revascularization of the patient’s extremities [105].
More recently, allogeneic MSC transplantation was
performed in ﬁve white patients with diffuse SSc. All
patients tolerated MSC transplantation without im-
mediate toxicity. Four of the ﬁve patients showed
improvement in the modiﬁed Rodnan skin score.
Acral necrosis improved, or healed, in all the affected
patients [106]. Furthermore, positive results have
been reported after the transplantation of autologous
ADSCs in hyaluronic acid solution in six SSc pa-
tients. The authors showed a signiﬁcant improve-
ment in tightening of the skin without complications
such as anechoic areas, fat necrosis or infections,
thus suggesting that ADSCs are a potentially valu-
able source of cells for therapy [107].
Although the use of MSCs in patients with SSc is
limited, another stem cell type is currently being
assessed as therapy for severe SSc. Since 2001, the
efﬁcacy, safety and long-term effects of autologous
hematopoietic stem cell transplantation in SSc have
been studied in one phase II and two phase III ran-
domized, controlled trials in Europe and North
America [108]. However, caution should be applied
before considering the positive improvement of MSC
transplantation, and further controlled studies must
be planned in this area to establish safety, efﬁcacy
and selection of appropriate patients.Osteogenesis imperfecta
Osteogenesis imperfecta (OI), or brittle-bone dis-
ease, is a genetic disease that is linked to dominant
mutations in the type I collagen genes, COL1A1 and
COL1A2, and is characterized by osteopenia and
multiple fractures, severe bony deformities and
considerably shortened stature. Two categories,
structural defects and quantitative defects, have been
reported [109,110].
Preclinical results
A murine model showed preclinical data that trans-
plantation of MSCs should attenuate, or evencorrect, genetic disorders of bone or cartilage. MSCs
obtained from wild-type mice were infused into a
mouse model of OI. The results showed that up to
12% of the donor cells were found in various tissues,
including bones. This ﬁnding suggested that MSCs
were able to home to the bones, differentiating into
osteocytes and producing of normal collagen type I
with possible partial restoration of the OI phenotype
[111]. Intrauterine transplantation of human fetal
MSCs in OI mice showed that MSCs were able to
decrease fracture rates and skeletal abnormalities,
thus correcting bone defects [112]. The marked
reduction of fracture rates and skeletal abnormalities
might suggest a scientiﬁc basis for MSCs in the
pathogenesis and future treatment of OI.Clinical therapy
Actually, only MSC-based cell and gene therapies
have shown positive effects in OI [113]. Horwitz et al.
[114] in 1999 transplanted allogeneic bone marrow
from HLA-identical or single-antigenemismatched
siblings into three children with OI. Three months
after engraftment, all patients showed positive results
[114]. Subsequently, isolated, puriﬁed and expanded
allogeneic MSCs, successively engrafted into six
children, were reported as feasible therapy for OI. In
fact, formation of new dense bone, increase in bone
mineral content and reduction in bone fracture fre-
quencies were observed [115]. More recently, a
novel clinical therapeutic option was published in
literature: MSC transplantation in uterus. In a fe-
male fetus with severe OI, allogeneic MSCs from an
HLA-mismatched male fetal liver of a 10-week
aborted fetus were injected. The cells were cultured
and injected into the umbilical vein at the 32nd week
of gestation. At 9 months of age after delivery,
analysis of the donor cells revealed 0.3% of the donor
cells. The follow-up revealed only three fractures
during the ﬁrst 2 years, normal psychomotor devel-
opment and correct growth tendency [116]. With the
development of gene therapy, MSCs have been
explored as a potential carrier for different genes in
OI treatment. Millington-Ward et al. [117] devel-
oped a mutation-independent short interfering RNA,
targeting a common intragenic a single nuclear pro-
tein in the COL1A1 gene, and the protein levels of
COL1A1 were suppressed by up to 85%. Therefore,
a good therapeutic effect might be achieved through
silencing the mutant allele and then replacing the
mutated gene with normal allele [117].Osteonecrosis of the femoral head
Osteonecrosis of the femoral head (ONFH), or avas-
cular necrosis of the femoral head, is a progressive
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blood supply to the bone and may lead to the total
collapse of femoral head. It is a painful disorder that
commonly affects 30- to 50-year-old individuals.
ONFH is a multifactorial disease, and the pathogen-
esis is still unknown. Late consequences of ONFH
include femoral head collapse and subsequent
degeneration of the hip joint [118,119].Preclinical results
Various preclinical investigations showed in different
animal models the therapeutic effectiveness of MSCs
on ONFH. These data pointed out that transplanted
autologous or allogeneic MSCs were capable of
survival, proliferation and differentiation into osteo-
blasts directly in the necrotic femoral head after
transplantation [120e123]. Furthermore, improve-
ment in necrosis repair and enhancement of bone
regeneration were reported. In addition, intrave-
nously implanted MSCs displayed good results by
migration and reparation of the injured tissues.
Furthermore, it has been recently reported that the
implanted MSCs not only proliferate and differen-
tiate into osteoblasts but also secrete angiogenic
cytokines [124,125].
MSCs transduced with different viral vectors car-
rying various genes have been explored to estimate the
potential effect of treatment on ONFH. The
enhancement of blood vessel regeneration, tissue
reparation and bone reconstruction in the ONFH
rabbit model was reported after transplantation of
hepatocyte growth factoretransgenic BM-derived
MSCs. Furthermore, the change in hepatocyte
growth factor concentration promoted MSC-
mediated osteogenic regeneration by increasing oste-
ogenic differentiation and proliferation of MSCs
[126,127].Clinical therapy
Autologous bone marrow grafts have been used for
the treatment for ONFH since 1991 [128], with good
results obtained [129,130], and these results have
been conﬁrmed by long-term follow-up studies [131].
Zhao et al. [132] evaluated 100 patients with
early-stage ONFH who were recruited and randomly
assigned to BM-derived MSC treatment or core
decompression treatment. The follow-up results at
different times after operations showed that the
BM-derived MSCs group had signiﬁcantly improved
clinical conditions, relieved pain and decreased
necrotic area in femoral head. No complication was
observed, pointing out that autologous BM-derived
MSC intervention is a safe and effective treatment
for ONFH [132].Recently, positive results of short-term regener-
ation of medullar boneelike tissue and long-term
reduction in hip pain after treatment of ADSCs in
patients with ONFH was reported. The authors
suggested that ADSC implantation might be a
promising minimally invasive therapy for ONFH
[133].
Although these data showed encouraging and
safe interventions in ONFH in delaying or avoiding
femoral head collapse, which may necessitate total
hip replacement, further experience and research are
needed.Osteoporosis
Osteoporosis (OP) is a common disease character-
ized by a systemic impairment of bone, including
mass, strength and microarchitecture, which
increases the propensity of fragility fractures. The
socioeconomic burden is relevant: approximately
40% of white postmenopausal women are affected by
OP, and their lifetime risk of fracture is until up 40%.
From a patient’s perspective, fractures, most
commonly occurring in the spine, hip or wrist, and
the subsequent loss of mobility often induce an
important decrease in the quality of life. Bone loss
occurs insidiously and is initially asymptomatic;
therefore, OP is often only diagnosed after that the
ﬁrst clinical fracture has occurred. Consequently, the
aim of therapy should be prevention of bone loss with
a consequent reduction of fractures [48].Pathogenesis
MSCs have a direct role in the maintenance of bone
balance and regeneration. They act through their
self-renewal and differentiating properties toward an
osteogenic lineage as a source of progenitors for os-
teoblasts, which are responsible for the anabolic
function of the homeostatic balance, and as regula-
tors for osteoclastogenesis. MSC differentiation to-
ward a speciﬁc lineage is dependent on hormonal
and local factors, which may activate speciﬁc tran-
scription factors. Any change in the pathways
involved in the differentiative process or in the
functional features of MSCs might have important
implications during aging and in some osteogenic
disorders such as post-menopausal OP [134].
Several authors studied growth, proliferation,
differentiation toward osteogenic potential, gene
expression and control of the microenvironment of
MSCs in OP patients, but the pathogenetic mecha-
nisms are still not fully elucidated and conﬂicting
data are reported [48,134,135].
Some evidence reported that in the BM micro-
environment, adipose tissue volume increased from
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furthermore, trabecular bone volume decreased from
26% to 16%, and these data are probably related to
an upregulation of pro-adipogenic and anti-
osteogenic signaling pathways that commit MSCs
toward adipocytes instead of osteoblasts. In addition,
it is well known that the number of MSCs committed
to the adipocytic lineage increased, whereas the
number of those committed to the osteoblastic line-
age decreased [136].
Recently, some authors studied the osteogenic
differentiation process in MSCs obtained from the
peripheral blood of OP patients and normal donors.
The results showed that circulating MSCs were
increased in OP patients compared with that in
healthy control subjects. However, gene expression
analysis revealed a downregulation of transcription
factors essential for osteoblastic differentiation, such
as RUNX-2, Sp7 and the bone-related genes
COL1A1, SPARC and SPP1 in OP patients.
Furthermore, lower levels of osteoprotegerin (OPG)
and receptor activator of nuclear factor-rB ligand
(RANKL) were reported. OPG acts as an inhibitor of
osteoclastogenesis, and the lower OPG/RANKL ra-
tio observed in OP patients might reﬂect a decreased
ability of osteoblasts to prevent osteoclast activation.
These authors suggested that an impaired osteoblast
differentiation might be associated with adipogenic
differentiation [135].
On the other hand, previous experience did not
support these ﬁndings, reporting no difference
among the number of osteoprogenitor cells, prolif-
erative potential and osteogenic commitment, dif-
ferentiation responses to stimulation by GH and
calcitriol [137].
Leptin is a paracrine-signaling molecule that
modulates the differentiation of stromal cells toward
osteoblasts. It inhibits cell differentiation to adipo-
cytes, and a functional leptin receptor has been
found in precursor cells of the osteoblasts lineage. It
has been reported that leptin signiﬁcantly inhibited
MSC differentiation toward normal adipocytes but
not in OP cells, exerting a low stimulatory osteogenic
effect; this impaired leptin action might be due to a
decreased leptin production by MSCs and/or a
reduced receptor-binding capacity. In addition,
normal MSCs display lower levels of peroxisome
proliferator-activated receptor-g protein that exerts a
protective effect on adipogenesis than the levels
observed in OP cells [138].
The effects of other factors contained in the sera
of OP patients were studied in postmenopausal OP
women, showing that OP MSCs, after stimulation,
may preferentially follow an adipocyte differentiation
route. Among them, estrogen inhibited osteoclastic
bone resorption, thus reducing the frequency of boneremodeling cycles; other factors, such as lipoprotein
lipase and glyceraldehyde 3-phosphate dehydroge-
nase, were able to induce the differentiation of MSC
adipocytes, lowering the number of osteoblasts. Bone
mass and fat mass are closely regulated during aging
and OP [134e138].Preclinical data
In 1994, Bruder et al. [139] proposed that the sys-
temic administration of culture-expanded autolo-
gous human MSCs might be used to treat OP. They
proposed that local bone defects might be repaired
through site-directed delivery of MSCs in an
appropriate carrier vehicle [139].
On these bases, in several animal models it has
been shown that transplantation of autologous or
allogeneic MSCs may be able to strengthen the
osteoporotic bone in MSC-transplanted animals. In
addition, MSCs showed a speciﬁc homing to the
surface of trabecular bone after directed injection of
these cells by intravenous transplantation [140,141].
The bone volume decrease associated with OP is
generally accompanied by an increased marrow adi-
pose tissue formation. In this regard, inhibition of
adipogenesis and an increase in osteoblastogenesis
might provide a novel therapeutic approach for
osteopenic disorders. Nuttall et al. [142] reported
that cells cultured from human trabecular bone are
not only osteogenic, but these cells are able to un-
dergo adipocyte differentiation under deﬁned culture
conditions; they induced osteoblast differentiation by
1,25-dihydroxyvitamin D3 and adipocyte differenti-
ation by dexamethasone plus 3-isobutyl-
1-methylxanthine (IBMX) treatment. Adipogenesis
and osteoblastogenesis were characterized by
lineage-speciﬁc enzyme and gene activities. The
results of this study provided evidence for a common
pluripotent MSC that is able to undergo either adi-
pogenesis or osteoblastogenesis. Adipogenesis can be
induced by long-chain fatty acids and/or the thiazo-
lidinedione troglitazone. Furthermore, the adipo-
genesis induced by dexamethasone associated with
IBMX can be inhibited by IL-1b, TNF-a and TGF-
b. Therefore, the authors concluded that the speciﬁc
inhibition of marrow adipogenesis and promotion of
osteoblastogenesis of a common precursor cell might
suggest a novel therapeutic approach to the treat-
ment of osteopenic disorders [142].
Human bone morphogenetic protein (BMP)-2,
BMP-4, BMP-6 and BMP-7 are involved the path-
ophysiological pathways of osteoporosis. Moreover,
BMP-2 plays a prominent role in osteo-induction: it
is able to increase both the number of MSCs and the
osteogenic activity by enhancement of proliferation
and reduction of apoptosis. Preliminary results about
Mesenchymal stromal cells and rheumatic diseases 13BMP-2 genetically engineered MSCs, transplanted
in OP mouse and sheep models, showed that these
cells were able to increase both bone regeneration
and fracture healing [143].
RANKL and receptor activator of nuclear factor-
rB (RANK) was reported to play an important role in
OP MSCs. RANK-Fc is a recombinant protein of
the extracellular domain of RANK fused to the Fc
region of human immunoglobulin G and targets as a
soluble antagonist against RANKL. Addition of
RANK-Fc in an in vitro model reduced the forma-
tion of osteoclasts [144].
The interaction among stromal cellederived
factor-1 and CXC chemokine receptor-4 (CXCR4)
is a well-known regulator of cell trafﬁcking and
homing in bone. Transplantation of MSCs over-
expressing CXCR4 alone or co-expressing CXCR4þ
RANK-Fc or CXCR4þ cbfa-1 displayed signiﬁcant
protection against ovariectomy induced bone loss.
Notably, co-expression groups of CXCR4 þ RANK-
Fc or CXCR4 þ cbfa-1 indicated more effective
results [145].Clinical data
More recently, human ADSCs were isolated from
patients affected by osteoporotic fractures. ADSCs
and BM-derived MSCs of the same donor were har-
vested and divided into two age groups. The ﬁrst
group included 14 young patients and the other group
included 8 elderly patients with osteoporotic frac-
tures. The authors showed that the doubling time of
ADSCs from both age groups was maintained below
70 hours, whereas that of BM-derived MSCs
increased signiﬁcantly with the number of passages.
When ADSCs and BM-derived MSCs from the same
patient were compared, there was a signiﬁcant in-
crease in the doubling time of BM-derived MSCs in
each individual from passages. As far as the osteogenic
induction is concerned, the level of matrix minerali-
zation by ADSCs from a group of elderly patients was
comparable to that of ADSCs from group of young
patients. However, BM-derived MSCs from a group
of elderly patients produced the least amount of
mineral deposits and had a lower expression level of
osteogenic genes. The p21 gene expression and
senescence-associated b-galactosidase activity were
lower in ADSCs compared with that in BM-derived
MSCs, which might partially be responsible for the
greater proliferation and differentiative rate of
ADSCs, and suggests a potentially effective role for
ADSCs in cell-based regenerative therapy in elderly
OP patients [146].
In conclusion, although MSCs demonstrated a
promising prospect of clinical application in OP,
until now, no report on clinical application of MSCsin OP patients has been published, and further
clinical studies must investigate their potential efﬁ-
cacy and safety.Conclusions
Stem cell therapies represent an innovative approach
for the treatment of rheumatic diseases, especially for
forms that are not responsive to standard treatments
or alternatively still lacking a deﬁnite therapy. At
present, although the data from scientiﬁc literature
seem to suggest that such treatments might be more
effective whether administered as soon as possible,
the use of MSCs in clinical practice is likely to be
restricted to patients with a long history of a severe
refractory disease [147,148]. Further results from
larger clinical trials are needed to corroborate
preclinical ﬁndings and human non-controlled
studies. On these bases, the source of MSCs, the
prognostic importance of donor-and-host HLA
matching and the optimal administration regime
must be further explored. Although no direct MSC-
related adverse effects have been reported, long-term
follow-up for patients receiving MSCs are needed.
Further advancement in the knowledge of MSCs
might provide information about the therapeutic role
of these cells in the treatment of many rheumatic
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